Previous studies indicated that topoisomerase Ⅱ is required in telomere recombination by which 15% of cancer cells maintain their telomere for survive. The structure of telomeres in Saccharomyces type Ⅱ survivors is similar to that of human cell lines that maintain telomeric DNA by this telomerase independent alternative lengthening of telomeres (ALT) pathway. The patent claims a method for screening topoisomerase Ⅱ (TOP Ⅱ) inhibitors using a genetic recombinant yeast strain (tlc1 rad51). Meanwhile, since telomere maintenance is a required step for cancer cells, the combination of a telomerase inhibitor and a topoisomerase Ⅱ inhitiror (ALT pathway inhibitor) might totally block the telomere maintenance and represent a valuable anticancer strategy.拓樸異構酵素Ⅱ有參與在15%癌細胞利用染色體重組方式延長端粒的機制中。本專利以實驗室裡建構的酵母菌株(tlc1 rad51)為模式生物,來篩選抑制拓樸異構酵素Ⅱ的抑制物,該酵母菌株(tlc1 rad51)因其延長端粒的方法類似於人類利用重組的方法而延長端粒的癌細胞。故尋找可以抑制它生長的化合物,再配合端粒酵素的抑制劑,便可以同時阻斷兩條癌細胞用來延長端粒的路徑,進而發展抑制人類癌細胞生長的新藥。
